What question did this study set out to answer?

To assess the safety profile and incidence of serious infection events when initiating subsequent biological DMARDs in rheumatoid arthritis patients previously treated with rituximab.

January 21, 2009Annals of the Rheumatic DiseasesOpen Access

Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients

View Full Paper

Ask AI

Bookmark

Authors

MGMark C. GenoveseEli Lilly (United States)FBFC BreedveldLeiden University Medical Center PEP. EmeryUniversity of Leeds

Discussion

Member takes

Implication

Clinical trial analysis reports stable serious infection rates with subsequent biological DMARDs in rheumatoid arthritis, indicating sequential biologic therapy does not increase infection risk.

Key Points

To assess the safety profile and incidence of serious infection events when initiating subsequent biological DMARDs in rheumatoid arthritis patients previously treated with rituximab.
Analyzed 2,578 rheumatoid arthritis patients participating in an international rituximab clinical trial programme who entered safety follow-up after receiving one or more courses of rituximab.
Tracked serious infection events in 185 patients who subsequently received another biological DMARD, including 153 who received one or more tumour necrosis factor inhibitors.
Peripheral B-cell depletion was present in 88.6% of patients at the time another biological DMARD was initiated.
Thirteen serious infection events occurred after rituximab but before initiating another biological DMARD (6.99 events/100 patient-years), compared to 10 events following another biological DMARD (5.49 events/100 patient-years), with no fatal or opportunistic infections reported.

Cite This Study

Genovese et al. (2009) studied this question.

synapsesocial.com/papers/6a85461cabe7e878c19651ca https://doi.org/10.1136/ard.2008.101675

View Full Paper

Ask AI

Bookmark

Implication

Clinical trial analysis reports stable serious infection rates with subsequent biological DMARDs in rheumatoid arthritis, indicating sequential biologic therapy does not increase infection risk.

Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients

Discussion

Member takes

Implication

Key Points

Cite This Study

Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider